Back to results
US 2009/0155389 A1Published application
Selective serotonin receptor inverse agonists as therapeutics for disease
AssigneeACADIA Pharmaceuticals Inc.
InventorsDavid M. Weiner, Robert E. Davis, Mark R. Brann
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.
Claims46
A pharmaceutical composition comprising:
- a first compound selected from the group consisting of an inverse agonist of a serotonin receptor, an antagonist of a serotonin receptor, and pharmaceutically acceptable salts thereof;
- and
- a second compound selected from the group consisting of a SSRI, a SNRI, a MAO-I, a TCA, an antipsychotic agent, a norepinephrine reuptake inhibitor, a dopamine agonist, an anti-insomnia drug, an anti-manic drug, an anti-phobia drug, the compound of Formula (II)
- and pharmaceutically acceptable salts thereof.
1 more element
A method of treating a disorder in a patient, the disorder selected from the group consisting of depression, mania, social phobia, psychosis, and a neuropsychiatric disorder, the method comprising:
- identifying a patient in need of said treatment, and
- administering to said patient a therapeutically effective amount of a combination of a first compound and a second compound, the first compound selected from the group consisting of an inverse agonist of a serotonin receptor, an antagonist of a serotonin receptor, and pharmaceutically acceptable salts thereof, the second compound selected from the group consisting of a SSRI, a SNRI, a MAO-I, a TCA, an antipsychotic agent, a norepinephrine reuptake inhibitor, a dopamine agonist, an anti-insomnia drug, an anti-manic drug, an anti-phobia drug, the compound of Formula (II)
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.